Market Analysis: Global Intracranial Hematoma Drug Market

Global intracranial hematoma drug market is expected to grow at a substantial CAGR of 6.4% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the rising cases of trauma, accidents, age related brain disorders, cancer among others, high prevalence of population suffering from hypertension and development in the healthcare expenditure and the government support for the research & development for new and better treatment have fueled the market growth.

Key Market Players:

The key market players in the global intracranial hematoma drug market are Pfizer Inc, Mylan N.V, Sun Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Medtronic, Spiegelberg GmbH & Co. KG, InfraScan, Inc, Integra LifeSciences Corporation, Arbor Pharmaceuticals, LLC, PDS Biotechnology, Orexo AB, Purdue Pharma L.P, Pharmaxis Ltd, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Idorsia Pharmaceuticals Ltd, AstraZeneca, Baxter, Penumbra, Inc, and others.

Market Definition: Global Intracranial Hematoma Drug Market

Intracranial hematoma is a condition which is characterized by the deposition of blood within the skull caused by bursting of blood vessel in the brain from any type of accident or trauma. The collection of the blood within the brain tissue or underneath the skull causes pressure on the brain tissues which damages the tissues leading to symptoms such as increasing headache, vomiting, drowsiness and progressive loss of consciousness, dizziness, confusion, unequal pupil size and slurred speech.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-intracranial-hematoma-drug-market

Market Drivers:

Rising cases of trauma, accidents, age related brain disorders, cancer among others may act as a market driver
Change in lifestyles such as smoking and alcohol consumption has increased the risk for Intracranial hematoma which acts as a market driver
Increased research and development initiatives and expenditure, is also expected to drive the market growth

Market Restraints:

Stringent regulations and approval procedure by the authorities for the treatment, is expected to act as a restraint to the market growth
Lack of awareness amongst people about optimal diagnosis and treatment of intracranial hematoma restricts the growth of this market
Associated side effects of the drugs are expected to impede the market growth
 Invasive nature of most intra-cranial pressure monitors which can hinder the market growth

Key Developments in the Market:

In June 2019, Zebra Medical Vision, Inc received FDA 510(k) clearance for HealthPNX an AI alert for Intracranial Hemorrhage and pneumothorax (PNX). This AI software automatically detects patient’s internal brain bleeds based on standard, non-contrast head CTs. The usage of this software can assist  in providing early detection in people suffering from high risk of severe brain bleeding events
In November 2018, MaxQ AI, Ltd received 510(k) clearance from FDA for Accipio Ix intracranial hemorrhage (ICH) detection software designed to detect non-contrast head CT images. The approval of this software will help in the early detection of the hematoma

Competitive Analysis:

Global intracranial hematoma drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of intracranial hematoma drug market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.